CASI Pharmaceuticals, Inc. received a final award from the Hong Kong International Arbitration Centre (HKIAC) in its arbitration proceeding against Juventas Co., Ltd. The tribunal rejected all allegations of breach of agreement by CASI and ruled that Juventas was the wrongful termination of agreements regarding CNCT-19 commercialization. The award includes recovery of wasted costs, interest, HKIAC costs, and legal costs totaling well over RMB 100 million. CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing anti-CD38 monoclonal antibodies for organ transplant rejection and autoimmune diseases.